EGFR and cancer: The representative first-generation EGFR-TKI (tyrosine kinase inhibitor) gefitinib induces apoptotic cell death via the intracellular Ca2+ and ROS release, the upregulating of Nox2 or Nox4, and the ER stress response in various cancer cell types [21,22].